Biotinylated Human BTLA (31-150) Protein, Fc, Avitag™ (MALS verified)

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Product Specifications

Background

Specifications

This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 42.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

AAP44003.1

Expression Region

Lys 31 - Ser 150

Host

HEK293

Target

BTLA

Conjugation

Biotin-labeled

Tag

C-Fc & C-Avi

Source

Human

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

95%

Bioactivity

Immobilized Human HVEM, His Tag (Cat. No. HVM-H52E9) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BTLA (31-150), Fc,Avitag (Cat. No. BTA-H82F3) with a linear range of 0.02-0.625 μg/mL (QC tested).